S2206: Phase III Trial of Neoadjuvant Durvalumab (NSC 778709) plus Chemotherapy versus Chemotherapy Alone for Adults with MammaPrint Ultrahigh (MP2) Hormone Receptor (HR) Positive / Human Epidermal Growth Factor Receptor (HER2) Negative Stage II-III Breast Cancer,
Details
Age
Adult
Locations
Cherry Creek Medical Center
Highlands Ranch Hospital
Lone Tree Medical Center
University of Colorado Hospital
Principal Investigator
Anthony Elias
Study ID
Protocol Number: 24-0401
More information available at ClinicalTrials.gov: NCT06058377
Categories
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers